Clinical trial NCT05967377: Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects
Official title: A Single Part, Open-Label, Randomised, Three-Way Crossover Study Designed to Evaluate the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib From Sorafenib (XS005) Tablets and Capsules Compared With Nexavar® (Reference Product) in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pharmacokinetics
Bioavailability
Lead sponsor: Xspray Pharma AB
Sponsor class: INDUSTRY
First posted: 2023-08-01
Enrollment: 15
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study.
Primary purpose: OTHER

Brief summary: This is a single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study in healthy male subjects comparing a 200 mg Sorafenib (Nexavar®) reference tablet (Regimen A) to XS005 Sorafenib Capsule A, 2 x 50 mg (Regimen B) and XS005 Sorafenib Tablet A,100 mg (Regimen C) formulation. It is planned to enroll 15 subjects who will receive single oral doses of investigational medicinal product (IMP) across 3 treatment periods.


Eligibility criteria: Inclusion Criteria:

1. Healthy males.
2. Age 18 to 55 years of age.
3. Body mass index (BMI) of 18.0 to 32.0 kg/m2.
4. Must be willing and able to communicate and participate in the whole study.
5. Must provide written informed consent.
6. Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), ECG and laboratory investigations (haematology, biochemistry and urinalysis).
7. Must adhere to the contraception requirements.

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the previous 3 months.
2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
3. Subjects who have previously been enrolled in this study.
4. History of any drug or alcohol abuse in the past 2 years.
5. Regular alcohol consumption \>21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type).
6. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission.
7. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.
8. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening.
9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator.
10. Subjects has amylase or lipase result exceeding \>1.5 x upper limit of normal (ULN) at screening.
11. Positive drugs of abuse or alcohol breath test result.
12. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results.
13. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder, as judged by the investigator.
14. Subject has a QT interval corrected by Fredericia (QTcF) \>450 ms based on ECG at screening or at pre-dose Period 1 or a history of additional risk factors for Torsades de Pointe (eg hypokalaemia, hypomagnesia, a family history of long QT syndrome).
15. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients.
16. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active.
17. Donation or loss of greater than 400 mL of blood within the previous 3 months.
18. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.
19. Subjects with pregnant partners.
20. Failure to satisfy the investigator of fitness to participate for any other reason.

Primary outcomes:
measure: Time of Maximum Observed Plasma Concentration (Tmax) of XS005 and Nexavar®
timeFrame: For each study period, blood samples collected at 15 time points (including pre-dose) during the study period on Day 1 and Day 4.
measure: Maximum Observed Plasma Concentration (Cmax) of XS005 and Nexavar®
timeFrame: For each study period, blood samples collected at 15 time points (including pre-dose) during the study period on Day 1 and Day 4.
measure: Area Under the Plasma Concentration-Time Curve from 0 time to the last measurable of concentration AUC(0-last) of XS005 and Nexavar®
timeFrame: For each study period, blood samples collected at 15 time points (including pre-dose) during the study period on Day 1 and Day 4.
measure: Area Under the Plasma Concentration-Time Curve from 0 time Extrapolated to Infinity (AUC0-inf) of XS005 and Nexavar®
timeFrame: For each study period, blood samples collected at 15 time points (including pre-dose) during the study period on Day 1 and Day 4.
measure: Plasma half-life of drug (T1/2) of XS005 and Nexavar®
timeFrame: For each study period, blood samples collected at 15 time points (including pre-dose) during the study period on Day 1 and Day 4.
measure: Relative bioavailability (Frel) of XS005 and Nexavar®
timeFrame: For each study period, blood samples collected at 15 time points (including pre-dose) during the study period on Day 1 and Day 4.
Secondary outcomes:
measure: Treatment-emergent adverse events (TEAEs) (ie those beginning after dosing with study drug)
timeFrame: Adverse event (AE) information collected through study completion, an average of 10 weeks.
measure: Systolic Blood Pressure (mmHg)
timeFrame: For each study period, Systolic Blood Pressure were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: Diastolic Blood Pressure (mmHg)
timeFrame: For each study period, Diastolic Blood Pressure were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: Heart Rate (HR) (bpm)
timeFrame: For each study period, HR were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: ECG (12-lead electrocardiogram) - Ventricular Rate (HR) (bpm)
timeFrame: For each study period, ECG were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: ECG (12-lead electrocardiogram) - PR Interval (msec)
timeFrame: For each study period, ECG were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: ECG (12-lead electrocardiogram) - QRS Duration (msec)
timeFrame: For each study period, ECG were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: ECG (12-lead electrocardiogram) - QT Interval (msec)
timeFrame: For each study period, ECG were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: ECG (12-lead electrocardiogram) - QRS Axis (°)
timeFrame: For each study period, ECG were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: ECG (12-lead electrocardiogram) - QTcF Interval (msec)
timeFrame: For each study period, ECG were collected at 4 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: Number of participants with abnormal laboratory values of Clinical Chemistry
timeFrame: For each study period, blood samples were collected at 2 time points (including pre-dose) during the study period on Day 1 and Day 2.
measure: Number of participants with abnormal hematology values
timeFrame: For each study period, blood samples were collected at 2 time points (including pre-dose) during the study period on Day1 and Day 2.
measure: Number of participants with abnormal urinalysis values
timeFrame: For each study period, urine samples were collected at 2 time points (including pre-dose) during the study period on Day1 and Day 2.
measure: Number of participants with abnormal physical examination outcome
timeFrame: For each study period, target (symptom driven) physical examination; each subject was assessed by a physician and a physical examination was performed if the subject reported any AEs, on Day 2.
measure: Number of participants with abnormal skin examination outcome
timeFrame: For each study period, skin assessments were done at 2 time points (including pre-dose) during the study period on Day 1 and Day 2.
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: Quotient Sciences
Study officials:
affiliation: Quotient Sciences
name: Sharan Sidhu, MBChB, BAO, MRCS, MFPM
role: PRINCIPAL_INVESTIGATOR
References: